Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  11:39 2022-06-24 am EDT
100.56 EUR   +5.02%
06/24Sanofi On Pace for Largest Percent Increase Since November 2020 -- Data Talk
DJ
06/24European Stocks Join Global Rally, Closes Week in the Green
MT
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi's Dupixent wins U.S. approval for bigger use

05/20/2022 | 02:42pm EDT
share with twitter
share with LinkedIn
share with facebook

May 20 (Reuters) - Sanofi on Friday won expanded U.S. approval for its best-selling Dupixent injection to treat an allergic inflammation of the esophagus, the U.S. Food and Drug Administration said. (Reporting by Ludwig Burger; Additional reporting by Eva Mathews; Editing by Maju Samuel)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS, INC. 0.84% 612.49 Delayed Quote.-3.01%
SANOFI 5.02% 100.56 Real-time Quote.13.52%
All news about SANOFI
06/24Sanofi On Pace for Largest Percent Increase Since November 2020 -- Data Talk
DJ
06/24European Stocks Join Global Rally, Closes Week in the Green
MT
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
06/24European shares mark strong end to nervous week
RE
06/24Sanofi, GSK variant-specific COVID shot found effective against Omicron
RE
06/24Sanofi, GSK COVID-19 Bivalent Vaccine Candidate Shows 72% Efficacy Against Omicron in P..
MT
06/24Sanofi, GSK Target COVID-19 Vaccine Availability in Late-2022 After New Positive Late-s..
MT
06/24Sanofi-GSK's COVID-19 Jab 72% Effective Against Omicron Variant in Late-stage Study
MT
06/24Sanofi says COVID-19 vaccine candidate yields positive trial data
RE
06/24Availability of the Q2 2022 Memorandum for modelling purposes
GL
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2022 41 842 M 44 137 M 44 137 M
Net income 2022 7 857 M 8 288 M 8 288 M
Net Debt 2022 6 634 M 6 998 M 6 998 M
P/E ratio 2022 15,8x
Yield 2022 3,51%
Capitalization 126 B 132 B 132 B
EV / Sales 2022 3,16x
EV / Sales 2023 2,93x
Nbr of Employees 95 442
Free-Float 88,0%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 100,56 €
Average target price 114,81 €
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI13.52%132 461
JOHNSON & JOHNSON5.02%479 678
ELI LILLY AND COMPANY13.21%293 110
PFIZER, INC.-15.17%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202